BioNexus Gene Lab (NASDAQ:BGLC) Stock Falls 6.5% – Should You Sell?

Posted by Linda Flegge on Sep 29th, 2026

BioNexus Gene Lab Corp. (NASDAQ:BGLC – Get Free Report) shares dropped 6.5% during trading on Monday. The company traded as low as $1.27 and last traded at $1.30. 11,408 shares changed hands during trading, an increase of 198% from the average daily volume of 3,831 shares. The stock had previously closed at $1.39.

Wall Street Analysts Forecast Growth

Separately, Weiss Ratings lowered BioNexus Gene Lab from a “sell (d-)” rating to a “sell (e+)” rating in a research note on Friday, September 18th. One research analyst has rated the stock with a Sell rating, Based on data from MarketBeat, BioNexus Gene Lab currently has a consensus rating of “Sell”.

Read Our Latest Stock Analysis on BGLC

BioNexus Gene Lab Price Performance

The business’s 50 day moving average price is $1.49 and its 200-day moving average price is $1.93. The company has a quick ratio of 5.28, a current ratio of 6.08 and a debt-to-equity ratio of 0.01. The company has a market cap of $3.81 million, a PE ratio of -1.03 and a beta of 4.19.

BioNexus Gene Lab (NASDAQ:BGLC – Get Free Report) last announced its earnings results on Friday, August 14th. The company reported ($0.12) earnings per share for the quarter. The firm had revenue of $0.08 million during the quarter. BioNexus Gene Lab had a negative net margin of 82.38% and a negative return on equity of 32.92%.

BioNexus Gene Lab Company Profile

(Get Free Report)

BioNexus Gene Lab Corp. (NASDAQ:BGLC) is a biotechnology and molecular diagnostics company focused on developing genetic tests intended to support the early detection of cancer and other diseases. Its diagnostic work uses blood-based and molecular analysis to identify biological indicators that may help healthcare providers assess disease risk and guide further evaluation.

The company operates through two primary business areas: Molecular Diagnostics and Chemical Trading. The Molecular Diagnostics segment develops and commercializes genetic testing products, while the Chemical Trading segment distributes industrial chemicals and related products to customers in its served markets.

BioNexus Gene Lab is headquartered in Kuala Lumpur, Malaysia, and its operations have included activities in the Malaysian market.